Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Pharmaceutical Business Review
Return to: PBR Home
Top Headlines

Pharmaceutical Business Review

Sanofi, Lonza to build EUR270m biologics production facility in Switzerland Sanofi and Lonza have agreed to invest an initial CHF290m (€270m) to construct a mammalian cell culture facility for monoclonal antibody production in Visp, Switzerland. Production & Manufacturing > Manufacturing > News
Pharma Two B raises $30m for trial of Parkinson's treatment Pharma Two B, a privately held biopharmaceutical firm engaged in the development of treatments for Parkinson’s disease, has closed $30m financing round.
Drug Research > Drug Discovery & Development > News Advaxis licenses antigen delivery technology to Sellas for cancer immunotherapy development Advaxis has licensed its Lm-based antigen delivery technology to Sellas, under a cancer immunotherapy collaboration that could generate up to $358m for Advaxis.
Contract Research & Services > Contract Services > News La Jolla’s blood pressure drug meets primary endpoint in phase 3 trial By PBR Staff Writer
La Jolla Pharmaceutical’s catecholamine resistant hypotension (CRH) drug, LJPC-501 (angiotensin II) has met its primary endpoint in a phase 3 study.
News
Sanofi, Lonza to build EUR270m biologics production facility in Switzerland By PBR Staff Writer
Sanofi and Lonza have agreed to invest an initial CHF290m (€270m) to construct a mammalian cell culture facility for monoclonal antibody production in Visp, Switzerland.
Production & Manufacturing > Manufacturing > News EMA's CHMP recommends approval of Novartis’ Tafinlar in combination with Mekinist The Committee for Medicinal Products for Human Use (CHMP) has recommended approval to the European Medicines Agency (EMA) of Novartis’ Tafinlar (dabrafenib) in combination with Mekinist (trametinib) as therapy for advanced or metastatic non-small cell lung cancer (NSCLC) patients whose tumors express the BRAF V600 mutation.
Production & Manufacturing > Process & Production > News Oxford BioMedica’s TroVax phase I/II trial yields encouraging results Oxford BioMedica announced that a phase I/II clinical trial of MVA-5T4 immunotherapy (TroVax) and low dose cyclophosphamide (CPM) has yielded encouraging results in patients with advanced colorectal cancer (TaCTiCC).
Contract Research & Services > Clinical Trials > News

Latest News and Insight by Sector

Production & Manufacturing

Sanofi, Lonza to build EUR270m biologics production facility in Switzerland
By PBR Staff Writer
Sanofi and Lonza have agreed to invest an initial CHF290m (€270m) to construct a mammalian cell culture facility for monoclonal antibody production in Visp, Switzerland.
Production & Manufacturing > Manufacturing > News
EMA's CHMP recommends approval of Novartis’ Tafinlar in combination with Mekinist
The Committee for Medicinal Products for Human Use (CHMP) has recommended approval to the European Medicines Agency (EMA) of Novartis’ Tafinlar (dabrafenib) in combination with Mekinist (trametinib) as therapy for advanced or metastatic non-small cell lung cancer (NSCLC) patients whose tumors express the BRAF V600 mutation.
Production & Manufacturing > Process & Production > News

Drug Research

Pharma Two B raises $30m for trial of Parkinson's treatment
Pharma Two B, a privately held biopharmaceutical firm engaged in the development of treatments for Parkinson’s disease, has closed $30m financing round.
Drug Research > Drug Discovery & Development > News
Advaxis licenses antigen delivery technology to Sellas for cancer immunotherapy development
Advaxis has licensed its Lm-based antigen delivery technology to Sellas, under a cancer immunotherapy collaboration that could generate up to $358m for Advaxis.
Contract Research & Services > Contract Services > News

Inward Investment

New WuXi Life Science to acquire WuXi PharmaTech for $3.3bn
Shanghai-based WuXi PharmaTech has entered into a merger agreement with New WuXi Life Science and its wholly owned subsidiary WuXi Merger, worth a total cash consideration of $3.3bn.
Inward Investment > News
PPF Group acquires minority stake in Cytune Pharma
By PBR Staff Writer
PPF Group, in cooperation with SOTIO has completed acquisition of minority stake in French biotechnology firm Cytune Pharma.
Inward Investment > News

Packaging

Catalent completes acquisition of Australia's Pharmapak
By PBR Staff Writer
US-based Catalent Pharma Solutions has strengthened its ability to provide integrated solutions to customers with the acquisition of Pharmapak Technologies, an Australian pharmaceutical packaging business.
Production & Manufacturing > OTC > News
MP Global Products introduces foam-free packaging for shipment of temperature sensitive pharmaceuticals
MP Global Thermal Packaging Products insulated protective mailers and box liners are specifically designed for temperature control and protection of mail order shipments of temperature sensitive pharma, pet meds, and natural and organic cosmetics.
Packaging > News

Contract Research & Services

Advaxis licenses antigen delivery technology to Sellas for cancer immunotherapy development
Advaxis has licensed its Lm-based antigen delivery technology to Sellas, under a cancer immunotherapy collaboration that could generate up to $358m for Advaxis.
Contract Research & Services > Contract Services > News
La Jolla’s blood pressure drug meets primary endpoint in phase 3 trial
By PBR Staff Writer
La Jolla Pharmaceutical’s catecholamine resistant hypotension (CRH) drug, LJPC-501 (angiotensin II) has met its primary endpoint in a phase 3 study.
News

Automation

Veeva rolls out cloud application to accelerate regulatory submission delivery
Veeva Systems (VEEV) announced a new cloud application dubbed Veeva Vault Submissions Publishing that incorporates publishing capabilities within Veeva Vault RIM to accelerate regulatory submission delivery.
Automation > IT & Software > News
Arven selects GE Healthcare’s manufacturing platform to expand production capacity at Turkish facility
GE Healthcare’s FlexFactory manufacturing platform has been selected to expand production capacity at Arven Pharmaceuticals' facility in Kirklareli, Turkey.
Automation > IT & Software > News

Regulatory Affairs

FDA grants priority review to Pfizer's antibody-drug conjugate for ALL
By PBR Staff Writer
The US Food and Drug Administration (FDA) has granted a priority review designation to Pfizer's anti-CD22 antibody-drug conjugate inotuzumab ozogamicin to treat patients with relapsed or refractory acute lymphoblastic leukemia (ALL).
Regulatory Affairs > News
European Commission conditionally approves Roche’s cancer drug Alecensa
By PBR Staff Writer
Roche's oral ALK inhibitor, Alecensa, has been conditionally approved in the European Union as a monotherapy for anaplastic lymphoma kinase-positive advanced non-small cell lung cancer (NSCLC) in adults who were earlier treated with crizotinib.
Regulatory Affairs > News



Data-Label.co.uk DataLabel have been supplying
the medical industry with labels
for over 10 years

Manufactures of
healthcare packaging
machinery